BARD1 Life Sciences
Follow
Follow Organisations, People and Lists
Stay on top of the latest updates for your desired data.
Industry Lists
Public Companies - Industrial
BARD1 Life Sciences is an ASX-listed Swiss-based biotech firm involved in the development and commercialisation of a blood test for the BARD1 protein biomarkers of early stage lung cancer.
In December 2015, the Perth-based resources company Eurogold announced that it would acquire BARD1AG in a reverse takeover deal. The deal completed with the re-listing of the company on the ASX as BARD1 Life Sciences in June 2016.
In July 2020, the company relocated its head office to Melbourne as a result of its acquisition of Sienna Cancer Diagnostics.
In December 2015, the Perth-based resources company Eurogold announced that it would acquire BARD1AG in a reverse takeover deal. The deal completed with the re-listing of the company on the ASX as BARD1 Life Sciences in June 2016.
In July 2020, the company relocated its head office to Melbourne as a result of its acquisition of Sienna Cancer Diagnostics.
Contact Details
Unit 202, Level 2, 39 Mends Street, SOUTH PERTH WA 6151
08 9381 9550
Lists and Charts
Share Price
Closing price for the last 90 trading days
Powered by Morningstar ®
Share Transactions
Total value as at the date of the transaction
Powered by Morningstar ®
Revenue
| Rank | Company | Revenue | |
|---|---|---|---|
| 153rd |  | BARD1 Life Sciences | $571k |
| 188th | | Altech Chemicals | $0 |
| 189th | | HearMeOut | $0 |
| 191st |  | Oakajee Corporation | $0 |
| 192nd | | Protean Energy | $0 |
199 listed industrial companies ranked by revenue.
Powered by Morningstar ®
Powered by Morningstar ®
Total Shareholder Return as at 31/07/20
| Rank | Company | 1 yr | 5 yr |
|---|---|---|---|
| 316th | Protean Energy | 23% | -61% |
| 420th | BARD1 Life Sciences | 0% | 6% |
| 543rd | Oakajee Corporation | -18% | -11% |
| 742nd | Altech Chemicals | -56% | -7% |
673 WA (and selected non WA) listed companies ranked by 1 year TSR relative to other companies with similar revenue
Powered by Morningstar ®
Powered by Morningstar ®
Public Companies - Industrial list sponsored by
Collapse All Lists and Charts
Article Timeline
Company Activity
| NEW ROLE: Tony Di Pietro, Chief Financial Officer, Company Secretary | 03 Aug 2020 |
| NEW ROLE: Carl Stubbings, Chief Operating Officer | 03 Aug 2020 |
| NEW ROLE: Helen Fisher, Non-Executive Director | 03 Aug 2020 |
| NEW ROLE: Geoffrey Cumming, Non-Executive Chair | 03 Aug 2020 |
| NEW ROLE: Peter French, Chief Scientific Officer from 17 August 2020 | 24 Jul 2020 |
| REMUNERATION UPDATE: Peter Gunzburg, Executive Chair, Managing Director | 30 Jun 2020 |
| REMUNERATION UPDATE: Irmgard Irminger-Finger, Executive Director, Chief Scientific Officer | 30 Jun 2020 |
| REMUNERATION UPDATE: Geoffrey Laurent, Non-Executive Director | 30 Jun 2020 |
| REMUNERATION UPDATE: Brett Montgomery, Non-Executive Director | 30 Jun 2020 |
| REMUNERATION UPDATE: Leearne Hinch, Chief Executive | 30 Jun 2020 |
